News | May 28, 2008

AAA Endovascular Repair Improves Mortality Rates

May 29, 2008 - A study of all U.S. Medicare hospital patients who had abdominal aortic aneurysm (AAA) repair between 2001 and 2003 shows that high volume hospitals that used endovascular, rather than open surgical approaches, had improved mortality rates.

Details of the study were revealed in the June 2008 issue of the Journal of Vascular Surgery. Statistics were collected from the national Medicare database by researchers who reviewed the impact of total hospital volume on operative mortality for all AAA repairs, and then compared both endovascular and open surgical procedures. Patients with ruptured AAAs were excluded from the study. The mortality rate was defined as death before discharge or up to 30 days after surgery. All analyses were adjusted for patient risk using logistic regression.

During the three-year study, 80,953 Medicare patients underwent AAA repair and an endovascular approach was used in 26,730 of the cases. Researchers found that hospital volume was significantly related to operative mortality in all comparisons. Mortality rates were 80 percent higher at hospitals in the lowest vs. the highest quartile of total volume when considering all types of repair together, and a similar relationship between total hospital volume and mortality was found when examining each approach separately.

"We found that the proportion of AAAs repaired by an endovascular approach increased from 27 percent to 39 percent during the study," said Justin B. Dimick, M.D., MPH, assistant professor at the University of Michigan and staff member of the Michigan Surgical Collaborative for Outcomes Research and Evaluation, University of Michigan Health Systems, both in Ann Arbor. "The highest volume hospitals used the endovascular approach 44 percent of the time compared to 18 percent at the lowest volume hospitals," he said. "This greater use of endovascular procedures accounted for 37 percent of the difference in mortality between high- and low- volume hospitals."

According to Dr. Dimick, endovascular repair also was associated with a much lower in-hospital mortality rate compared to open repair (6.6 percent vs. 2.5 percent). Mortality rates also were lower for endovascular repair in both elective (2.1 vs. 5.0 percent) and urgent/emergency (5.1 percent vs. 11.2 percent) operations.

"To our knowledge we are the first study to perform a systematic analysis since the introduction of the endovascular approach," said Dr. Dimick. "Our results show that hospital volume is still a valid quality indicator for AAA surgery. Some researchers used to think endovascular technology would change referral patterns, altering case-mix distribution and potentially diminish the apparent volume effect; our study proves that referral patterns have not altered the impact of volume on outcome. Also, our data shows that high volume hospitals are doing fewer open repairs, but still have very low mortality rates for open repair. These data clearly show that high volume hospitals are performing well despite any changes in referral patterns."

Dr. Dimick added that it is important to continue to investigate the relationship between volume and outcome as use of endovascular technology increases. "By investigating outcomes in the next five to 10 years it will become evident whether endovascular technology contributes to the existing relationship between volume and outcome for AAA repair, or if changes are due to a position on the learning curve or are true steady-state volume/mortality relationships," he said.

Dr. Dimick added that although the present study demonstrates that the volume effect is still present, it does little to resolve the ongoing debate about using volume as a proxy for quality. However, information on hospital volume can be used to improve the quality of care of AAA surgery by 1) steering patients to high volume hospital by using public reporting or various financial incentives and 2) having quality of care at all hospitals through can be achieved through collaborative quality improvement.

"Hospital volume in and of itself does not produce better outcomes," said Dr. Dimick. "However, underlying processes of care that differ between high and low-volume settings are responsible for the difference in outcomes." He noted that it is not known which approach, selective referral or quality improvement, will yield the greater results.

For more information:

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init